Matteo Lambertini, MD PhD· @matteolambe · X·· 22 hours agoScore45
Body · original
Oral abstract #BreastCancer session at #ESMO26: very promising data with the bispecific anti-HER2 antibody #anbenitamab plus an experimental taxane #HB1801 as first-line therapy in advanced #HER2+ disease
@OncoAlert @myESMO
54 views · 4 likes · 4 reposts · 0 replies
Conference abstracts
LBA15matched by Proffered paper 2: Breast cancer, early and advanced stage
Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.orgLBA80matched by Rapid oral 1: Gastrointestinal tumour, upper digestive
Anbenitamab plus chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Updated overall survival (OS) analysis of KC-WISE
https://esmocongress.esmo.orgSource: Matteo Lambertini, MD PhD · x.com